Clinica 100: GE Healthcare focuses on organic growth and emerging markets to stay on top
This article was originally published in Clinica
GE Healthcare has moved up in this year's Clinica 100 ranking from number three to number two in the medtech market, but will need to maintain growth to hold on to its spot. Its strategy includes targeting the emerging markets and focusing on organic growth, among other things, while keeping one eye on bolt-on acquisitions. Madeleine Armstrong spoke to president and CEO of GE Healthcare Europe, Jean-Michel Malbrancq, to find out more
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.